• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ESMO20 YO for YO: highlights on new drugs in advanced breast cancer focusing on sacituzumab govitecan and alpelisib.

作者信息

Lambertini M, Punie K

机构信息

Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy; Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.

Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.

出版信息

ESMO Open. 2021 Feb;6(1):100018. doi: 10.1016/j.esmoop.2020.100018. Epub 2020 Dec 15.

DOI:10.1016/j.esmoop.2020.100018
PMID:33399081
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7910735/
Abstract
摘要

相似文献

1
ESMO20 YO for YO: highlights on new drugs in advanced breast cancer focusing on sacituzumab govitecan and alpelisib.
ESMO Open. 2021 Feb;6(1):100018. doi: 10.1016/j.esmoop.2020.100018. Epub 2020 Dec 15.
2
Sacituzumab Govitecan: First Approval.Sacituzumab Govitecan：首次批准。
Drugs. 2020 Jul;80(10):1019-1025. doi: 10.1007/s40265-020-01337-5.
3
Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
Lancet. 2024 Jul 27;404(10450):338-339. doi: 10.1016/S0140-6736(24)01047-X.
4
Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
Lancet. 2024 Jul 27;404(10450):337-338. doi: 10.1016/S0140-6736(24)01045-6.
5
Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
Lancet. 2024 Jul 27;404(10450):339. doi: 10.1016/S0140-6736(24)01048-1.
6
Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
Lancet. 2024 Jul 27;404(10450):338. doi: 10.1016/S0140-6736(24)01046-8.
7
Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial - Authors' reply.
Lancet. 2024 Jul 27;404(10450):339-340. doi: 10.1016/S0140-6736(24)01049-3.
8
Sacituzumab govitecan-hziy for triple-negative breast cancer.戈沙妥珠单抗-hziy用于三阴性乳腺癌
Lancet Oncol. 2019 Apr;20(4):e194. doi: 10.1016/S1470-2045(19)30074-9. Epub 2019 Feb 28.
9
Sacituzumab govitecan activity in advanced breast cancer.戈沙妥珠单抗在晚期乳腺癌中的活性。
Lancet Oncol. 2017 May;18(5):e246. doi: 10.1016/S1470-2045(17)30232-2. Epub 2017 Mar 23.
10
Overall Survival Benefit with Sacituzumab Govitecan in Metastatic Breast Cancer: A Post Hoc Interaction Analyses of a Randomized Controlled Trail.戈沙妥珠单抗治疗转移性乳腺癌的总生存获益：一项随机对照试验的事后交互分析
Clin Drug Investig. 2024 Jun;44(6):455-457. doi: 10.1007/s40261-024-01367-x. Epub 2024 Jun 5.